INmune Bio, Inc. (INMB)

INmune Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.13	0.16	0.37	0.18	0.01	0
Revenue Growth (YoY)	-47.39%	-58.56%	106.63%	1545.45%	-	-
Gross Profit	0.13	0.16	0.37	0.18	0.01	0
Selling, General & Admin	9.63	9.62	9.26	8.79	6.32	6.02
Research & Development	24.83	20.27	17.07	20.54	5.92	3.28
Other Operating Expenses	0.27	0.27	1.35	1.19	0	-1.54
Operating Expenses	34.73	30.16	27.67	30.52	12.24	7.76
Operating Income	-34.6	-30.01	-27.3	-30.34	-12.23	-7.76
Other Expense / Income	-0.11	-	-	-	-0.13	-0.08
Pretax Income	-34.5	-30.01	-27.3	-30.34	-12.1	-7.68
Net Income	-34.5	-30.01	-27.3	-30.34	-12.1	-7.68
Shares Outstanding (Basic)	18	18	18	16	12	10
Shares Outstanding (Diluted)	18	18	18	16	12	10
Shares Change	0.45%	0.30%	11.14%	34.55%	16.70%	18.39%
EPS (Basic)	-1.92	-1.67	-1.52	-1.88	-1.01	-0.75
EPS (Diluted)	-1.92	-1.67	-1.52	-1.88	-1.01	-0.75
Free Cash Flow	-18.32	-11.98	-22.69	-28.5	-8.94	-5.38
Free Cash Flow Per Share	-1.02	-0.67	-1.26	-1.77	-0.75	-0.52
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-26413.74%	-19360.00%	-7299.20%	-16762.43%	-111163.64%	-
Profit Margin	-26333.59%	-19360.00%	-7299.20%	-16762.43%	-109990.91%	-
Free Cash Flow Margin	-13980.92%	-7729.03%	-6065.78%	-15748.07%	-81300.00%	-
EBITDA	-34.5	-30.01	-27.3	-30.34	-12.1	-7.68
EBITDA Margin	-26333.59%	-19360.00%	-7299.20%	-16762.43%	-109990.91%	-
EBIT	-34.5	-30.01	-27.3	-30.34	-12.1	-7.68
EBIT Margin	-26333.59%	-19360.00%	-7299.20%	-16762.43%	-109990.91%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).